Women We Admire is pleased to announce The Top 50 Women Leaders of New Jersey for 2025 NEW YORK, Nov. 2, 2025 /PRNewswire-PRWeb/ -- Women We Admire is pleased to announce The Top 50 Women Leaders of New Jersey for 2025. Though small in size, New Jersey's influence is outsized—home to one of the highest concentrations of scientists and engineers per square mile in the U.S. Its economy spans pharmaceuticals, logistics, finance, and beyond, anchored by its strategic location between New York and Philadelphia. ...

Core Points - Dr. Casaretto, a long-time medical professional, used Johnson & Johnson's talcum powder daily and later developed malignant mesothelioma, leading to his death in December 2022 [1][2] - His case provides a significant exposure history in talc litigation, with experts finding asbestos in his product despite no known asbestos exposure in his career [2] - Allegations against Johnson & Johnson claim that their talc products, marketed as "gentle" and "safe," were contaminated with asbestos, and the company concealed these risks for decades [3]

Core Insights - The competition for the title of "King of Drugs" is intensifying, with Eli Lilly's weight loss drug, Tirzepatide, leading sales in the first three quarters of the year, surpassing Merck's Keytruda [2][3] - Major pharmaceutical companies, including Johnson & Johnson, Roche, and Merck, have raised their annual revenue guidance following strong third-quarter performances [5][6][7] Group 1: Company Performance - Johnson & Johnson reported total revenue of $69.63 billion, leading the industry, with pharmaceutical revenue at $44.64 billion [4] - Eli Lilly achieved pharmaceutical revenue of $45.89 billion, driven by Tirzepatide, which generated $24.8 billion in sales [3][5] - Merck's total revenue reached $48.61 billion, with pharmaceutical revenue at $43.3 billion; however, sales growth for Keytruda has slowed [7] Group 2: Drug Sales Highlights - Tirzepatide's sales for the first three quarters reached $24.84 billion, with a significant increase in sales for its diabetes version, Mounjaro, which saw a 109% year-on-year growth [3] - Keytruda's sales were $23.30 billion, reflecting an 8% growth, but the growth rate is slowing down [7] - Roche's Phesgo saw a 54% increase in sales, contributing to a pharmaceutical revenue of approximately $42.55 billion [6] Group 3: Revenue Guidance Adjustments - Eli Lilly raised its full-year revenue guidance to between $63 billion and $63.5 billion [5] - Johnson & Johnson adjusted its revenue forecast to grow by 4.8% to 5.3%, targeting $93 billion to $93.4 billion [5] - Roche also increased its annual revenue expectations based on strong third-quarter results [6]

In October 2025, Timothy Mellon, a grandson of Andrew Mellon, was reported by The New York Times to have anonymously donated $130 million to the US government to fund the paychecks of United States Armed Forces members during the government shutdown.Andrew Mellon might be one of the most recognizable names to come out of the Gilded Age , but unlike other fortunes of the era, his has remained with the family. Mellon served as the US Secretary of the Treasury between 1921 and 1932, founded Union Steel in 1899 ...

Key TakeawaysMajor U.S. stock indices closed higher, with the Dow Jones up 0.15%, the S&P 500 gaining 0.31%, and the Nasdaq leading the rally with a 0.70% increase.Pfizer (PFE) received early U.S. Federal Trade Commission (FTC) clearance for its Metsera acquisition, a crucial step forward in its strategy to enter the rapidly growing obesity drug market.Johnson & Johnson (JNJ) submitted an application to the U.S. FDA for Stelara® (ustekinumab) for the treatment of pediatric ulcerative colitis, aiming to expa ...

Core Viewpoint - The 8th China International Import Expo (CIIE) will take place from November 5 to 10 at the National Exhibition and Convention Center in Shanghai, featuring over a hundred innovative products from Johnson & Johnson's medical technology and innovative pharmaceutical sectors, including several debut products [1][2] Group 1: Product Innovations - Johnson & Johnson will showcase the world's first 3D stapler endoscope, which utilizes a new 3D stapling technology to ensure optimal tissue alignment and a dynamic adjustment feature for the stapling process [1] - The Haishan endoscopic surgical robot, China's first modular endoscopic surgical robot, will make its debut at the expo, approved for four major specialty indications: general surgery, thoracic surgery, gynecology, and urology [1] Group 2: Strategic Partnerships - In September, Johnson & Johnson Medical Technology announced a strategic partnership with Chinese company RuLong Surgical to advance the commercialization of surgical technology in China, combining their product strengths to meet clinical needs [1] Group 3: CIIE Participation - Johnson & Johnson has evolved from a "first-time exhibitor" to a "permanent partner" at the CIIE, showcasing over a thousand innovative products and solutions, including hundreds of global and China debuts [2] - The company views the CIIE as a strategic platform for open innovation and collaboration in the healthcare sector, successfully creating a virtuous cycle of "exhibits - products - investments" that resonates with the high-quality development of China's healthcare industry [2]

Core Insights - The concept of "AI literacy" is becoming essential for job seekers and employees, with mentions of related terms in earnings calls increasing by nearly 800% in the past year [2][4] - A significant number of professionals feel nervous or embarrassed about their AI knowledge, with 35% feeling too anxious to discuss AI at work and 33% feeling inadequate in their understanding [4][5] - The workplace culture is fostering a "shame spiral" that discourages curiosity and open discussions about AI, leading to a lack of engagement and understanding [4][5] Industry Impact - Companies are rapidly replacing roles with AI tools without adequately training workers, leading to feelings of impostor syndrome among employees [4][5] - AI systems are making critical decisions without sufficient oversight, which can result in biased outcomes, as seen in cases like Amazon's AI recruiting tool and Workday's screening tools [5][6] - The need for a cultural shift towards vulnerability and openness in discussing AI is emphasized, as leaders should model the behavior they wish to see in their teams [6][7] Recommendations for Improvement - Organizations should create environments that allow employees to ask basic questions and admit gaps in their knowledge, fostering a culture of learning [6][7] - Companies like JPMorgan and Johnson & Johnson have successfully implemented low-stakes experimentation with AI, encouraging leaders to admit when they are unsure, which builds trust and accelerates adoption [8][9] - Emphasizing the importance of saying "I don't know" can empower employees to engage with AI more confidently and contribute to a more inclusive workplace [9]

Group 1 - The article discusses Kenvue (KVUE), the former consumer health division of Johnson & Johnson (JNJ), and rates the stock a "sell" due to strong overvaluation and expectations of limited risks with decent to high upside [1] - The analysis emphasizes the importance of identifying undervalued stocks while focusing on risk and reward, suggesting that the best investment ideas are often the simplest and contrarian approaches may yield better results [1]

10月27日，强生"此地无银"公益项目升级暨银屑病患者生涯发展洞察调研启动会上，北京大学第一 医院皮肤科主任医师李若瑜介绍："银屑病患者重返正常学习和工作，离不开长期稳定的病情控制。虽 然银屑病目前仍无法根治，但已有国际研究表明，早期使用合适的生物制剂，从规范的1年治疗开始， 通过长程管理，患者可以实现长达2.5年的皮损缓解 。希望更多患者可以通过科学治疗，重新掌握人生 节奏。"据介绍，该活动由强生创新制药发起、民生周刊杂志社公益支持，作为本次项目升级亮点，强 生创新制药基于深刻患者洞察，支持创作了银屑病领域首部AI短片《寻找李百银的23种可能》。 强生创新制药免疫领域负责人潘昉玥表示："深耕中国免疫领域近20载，'患者为先'是我们一切行 动的根本准则。从持续引入创新治疗方案，以满足银屑病患者日益增长的治疗需求，到通过数字化手段 为银屑病患者提供从用药到长期管理的全周期支持，再到聚焦患者治疗之外的需求，创新打造赋能公益 新模式，我们不断探索和优化患者支持的综合路径。"(中国经济网记者 韩璐) 10月29日为"世界银屑病日"。今年(2025年)，国际银屑病协会联合会(IFPA)以"停止多米诺骨牌效 应"为主题， ...

Accessibility StatementSkip Navigation The EPIC study will evaluate treatment with IMAAVYâ"¢ versus efgartigimod in adults with gMG and will include a treatment-switch arm The Company also announced new data from the pivotal Vibrance-MG study in which pediatric patients receiving treatment with IMAAVYâ"¢ demonstrated 72 weeks of sustained reduction in immunoglobulin G (IgG), sustained disease control and no new safety concerns IMAAVYâ"¢ is the only FcRn blocker for anti-AChR and anti-MuSK antibody positive ...